Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1656-1663

  Balmaña, Judith ^a   Tung, N M ^b   Isakoff, S J ^c   Grana B ^a   Ryan, P D ^c,g   Saura, C ^a   Lowe, E S ^d   Frewer, P ^d   Winer, E ^e   Baselga, J ^f   Garber, J E ^e  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Cisplatin; Olaparib

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR; OLAPARIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BRCA2 GENE; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVARY TUMOR; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TINNITUS; TUMOR SUPPRESSOR GENE; VOMITING; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EXPOSURE; NEUTROPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; TREATMENT OUTCOME;

EID: 84905183020     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu187     Document Type: Article

References (24)

1. Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005; 4: 1176-1178.
2. Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-5599.
3. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
4. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-3790.
5. Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011; 585: 1-6.
6. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
7. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
8. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
9. Ledermann JA, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 2013; 31(15 Suppl): abst 5505.
10. Jacob DA, Bahra M, Langrehr JM et al. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 2007; 22: 738-748.
11. Miknyoczki SJ, Jones-Bolin S, Pritchard S et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2: 371-382.
12. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
13. Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
14. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
15. Rajan A, Carter CA, Kelly RJ et al. A Phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18: 2344-2351.
16. Samol J, Ranson M, Scott E et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a Phase I study. Invest New Drugs 2012; 30: 1493-1500.
17. Khan OA, Gore M, Lorigan P et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104: 750-755.
18. AstraZeneca. Global Policy: Bioethics. 2011. http://www.astrazeneca.com/ Responsibility/Code-policies-standards/Our-global-policies (2 January 2014, date last accessed).
19. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
20. Lee J, Annunziata CM, Hays JL et al. Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). J Clin Oncol 2013; 31(15 Suppl): abst 2514.
21. Oza AM, Cibula D, Oaknin A et al. Olaparib plus paclitaxel + carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinumsensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label Phase II study. J Clin Oncol 2012; 30(15 Suppl.): abst 5001.
22. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
23. Isakoff SJ, Goss PE, Mayer EL et al. Impact of BRCA1/2 mutation status in TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Res 2012; 72: abstr PD09-03.
24. Byrski T, Dent R, Blecharz P et al. Results of a phase II open-label, nonrandomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14: R110.